This week’s episode of our “How Does It Work?” series features Peptide-Oligonucleotide Conjugates. Peptide-oligonucleotide conjugates are made up of peptide and oligonucleotide components. These cutting-edge molecules have many applications in biomedicine. The oligonucleotide component can interact with mRNA to alter gene expression within diseased cells but oligonucleotides are easily degraded in the body and have …Read More >

In this week’s installment of our “How Does It Work?” video series, we explore Antibody Drug Conjugates. Monoclonal antibodies are highly versatile molecules that we can modify to generate new and improved cancer therapies. Here we have a type of modified antibody, known as an antibody drug conjugate, or ADC. The ADC contains two antigen …Read More >

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

While chemo- and radio-therapy are considered the first-line of treatment for most cancers, its serious side effects have led to continuous innovation and discovery of new anti-tumor treatments. Oncolytic viruses (OVs) possess a magnitude of mechanism of action to elicit anti-tumor immune response, including OVs innate cytotoxicity and enhanced anti-tumor immunity by inserting immunomodulatory genes. …Read More >

We offer a wide range of oligonucleotide services, including: Sequence design Knockdown effect in cell lines and primary cells Splicing analysis Functional assays and assessment of off-target effects Transgenic, HDI and AAV mouse models GalNAc-ASGPR delivery system and customized assays for other delivery systems Stability and protein-protein binding assays Delivery/RISC PK in mouse, rat, and …Read More >

As part of our dedication to providing an #openaccess platform, so our entire ecosystem can come together to share #science & #collaborate to better the lives of all #patientsfirst. We’ve created MoA animations in our new series exploring biotech topics on a molecular level. First up, we explain the intricacies of how targeted protein degradation …Read More >

Recent years have seen a huge surge of interest in oligonucleotide therapeutics, fueled by major advances in our understanding of how to make such molecules stable, selective, and efficient as drug modalities. The field is now diverse in terms of therapeutic areas being addressed, biological processes being manipulated and delivery technologies employed. In this webinar, …Read More >